This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Cancer Gene Therapy Market

Market Insights on Cancer Gene Therapy covering sales outlook, demand forecast & up-to-date key trends

Cancer Gene Therapy Market by Therapy, Indication, Service Provider & Region - Forecast 2022 – 2032

Cancer Gene Therapy Market Outlook (2022-2032)

[300+ Pages Report] The global demand for the cancer gene therapy is expected to increase at a 10.1% CAGR from 2022 to 2032, reaching US$ 2 Bn in 2022. As per Future Market Insights (FMI), the oncolytic virotherapy segment held 49.3% of the overall global cancer gene therapy market in 2021, which is projected to be valued at US$ 5.3 Bn in the year 2032.

Data Points

Market Insights

Cancer Gene Therapy Market Base Year Value (2021)

US$ 1.9 Bn

Estimated Market Size (2022)

US$ 2.0 Bn

Projected Market Valuation (2032)

US$ 5.3 Bn

Value-based CAGR (2022-2032)

10.1%

Market Share of Top 5 Countries

74.8%

The global market of cancer gene therapy accounted for nearly 45.2% of the overall global gene therapy market worth around US$ 4.0 Bn in 2021.

Initially, gene therapy for monogenetic illnesses was popular; however, gene therapy for cancer treatment is growing in popularity. Cancer gene therapy is a method of treating cancer patients by introducing therapeutic DNA into their bodies.

Customize this Report

Let us know your requirement to get
100% FREE customization

2017-2021 Cancer Gene Therapy Market Historic Outlook Vs 2022-2032 Forecast

Demand for cancer gene therapy is forecast to increase at a 10.1% CAGR over the forecast period, in comparison to the 7.1% CAGR registered between 2017 to 2021.

Multiple mutations in a single cell cause cancer to spread. Cancer cells infiltrate new cell, have a rapid metabolism, and are constantly altering shape. Surgery, radiation therapy, and chemotherapy are options for cancer treatment. Gene therapy is utilised if the abovementioned treatments do not deliver the intended results.

In gene therapy, a functional gene, also known as therapeutic DNA, is inserted into the cells of a cancer patient to modify metabolism, alter or repair acquired genetic abnormalities, and impart new functions to cells.

For the last two decades, gene therapy has been a hot topic of research. Ten gene therapy products have been authorized for marketing in at least one country as of January 28, 2018. According to recent forecasts, 12 to 14 new gene therapies will be filed for approval in the following few years, with roughly 40 new medicines approved by the end of 2022.

Oncolytic viral therapy, gene transfer, and gene-induced immunotherapy are examples of cancer treatments. Gene therapy can be used in a variety of ways. For instance, replacing missing or defective genes with healthy genes, altering gene regulation, or introducing foreign genes into cells to alter their function or survival.

Electroporation, magnetofection, naked / plasmid vectors, sonoporation, and gene guns are examples of transgene treatment. Gene-induced immunotherapy is projected to dominate the global cancer gene therapy market over the forecast period.

Various organizations are investing heavily in cancer research. For Instance, in October 2017, American Cancer Society (ACS) approved a US$ 39.8 million funding for 78 training and research grants. These grants were awarded to researchers at 57 institutions across the U.S.

This has brought about significant developments in the field of cancer research and has led to further growth in the global oncogene therapy market.

Governments in various underdeveloped nations are actively taking steps to stimulate various research efforts aimed at producing cancer gene therapy and treatment plans to lower mortality and morbidity rates, which will drive the market.

Because of its high success rate in preclinical and clinical trials, cancer gene therapy is gaining prominence. The most popular method of cancer gene therapy is to replace a cancer-causing mutant gene with a healthy copy of the gene.

Cancer Gene Therapy Market Download Report Brochure

What Are The Key Opportunities For Cancer Gene Therapy Market Players?

Rising success rates of novel medicines and ethical acceptability of gene therapy for cancer treatment will create lucrative opportunities for cancer gene therapy market players. For instance, in August 2017, the US Food and Drug Administration (USFDA) approved an innovative treatment for children suffering from acute lymphoblastic leukemia. This gene therapy, “tisagenlecleucel (Kymriah™)”, is the first to be approved for cancer by the USFDA.

Gene therapy is one of the conceivable treatments suitable to the senior population with low to intermediate risk, according to respondents. In the U.S., cancer gene therapy is widely accepted. As a result, experts have emphasized that cancer gene therapy is deemed safe in the older population, and that the danger associated with gene therapy is minimal.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Factors Are Restraining The Demand For Cancer Gene Therapy?

The high costs associated with gene therapy, along with a detrimental immune response are expected to impede the growth in the cancer gene therapy market during the forecast period.

The availability of other cancer treatment types such as chemotherapy and surgery is expected to limit sales. Viruses are the most efficient biological vectors for delivering genes to target cells. Due to safety concerns, non-viral vector delivery systems could be used as a safer alternative.

The shortage of qualified medical professionals for cancer gene therapy in developing countries can hinder the growth of the global cancer gene therapy market.

According to government data and Indian medical association, less than 1,600 oncologists are treating an estimated 1 million cancer patients in the country, with a 20% increase in cancer cases by the end of the decade.

Country-wise Insights

What is the U.S. Cancer Gene Therapy Market Outlook?

“Rising Awareness Regarding DNA Therapy for Cancer in the U.S. Will Augment Growth”

The U.S. dominated the North America cancer gene therapy market, holding 96.8% of the total market share in 2021, and the trend is expected to continue over the assessment period.

Breast cancer is one of the most frequent diseases in women worldwide, according to the Centers for Disease Control and Prevention (CDC), and it remains the second-largest cause of cancer death in women worldwide, fuelling the expansion of the cancer gene therapy industry. With a high prevalence of cancer in the country, the U.S. market is set to expand at a lucrative rate throughout assessment period.

Why is the China Cancer Gene Therapy Market Considered Lucrative?

“Increasing Adoption of Genetic Mutation Lung Cancer Treatment in China Will Boost Sales”

Sales in China are set to account for 32.3% of the East Asia cancer gene therapy market by 2032. The 'Regulations on the Management of Clinical Application of New Biomedical Technologies' and 'Regulations on the Safety Management of Biotechnology Research and Development' have been drafted by China's national health, scientific, and technology agencies.

The purpose of improving the rules and regulations is to create a more reasonable supervisory mechanism, strengthen supervision, increase legal responsibility, and encourage healthy development of biotechnology research, applications, and related businesses. Such developments are expected to bode well for the market over the forecast period.

What is Driving the Germany Cancer Gene Therapy Market?

“Increasing Demand for Gene Targeted Chemotherapy in Germany Will Steer Sales”

Demand in Germany is projected to increase at a CAGR of 11.9% during the forecast period. Manufacturers, healthcare professionals, and patients are hopeful as regulators create a defined path for speedy access to novel cancer gene therapies.

Players, on the other hand, are analysing the new medicines' added benefits. In the realm of gene treatments, major advancements are expected in the forthcoming years, thereby fueling sales in Germany.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-Wise Insights

Which Cancer Gene Therapy is Driving the Market?

“Demand for Oncolytic Virotherapy Will Gain Traction”

Based on therapy, the oncolytic virotherapy accounted for about 49.3% of the total market share in 2021. Sales in this segment are expected to increase at a 9.5% CAGR over the forecast period.

Oncolytic virus therapy is a promising new therapeutic approach for cancer treatment that has recently been identified. An oncolytic virus is a genetically designed or naturally occurring virus that may selectively reproduce in cancer cells and kill them while causing no harm to normal tissues. Oncolytic virus therapy differs from gene therapy in that it exploits the virus as an active pharmacological reagent rather than just a carrier for transgene delivery.

Which Indication Category is Leading the Cancer Gene Therapy Market?

“Sales of Cancer Gene Therapy for Breast Cancer to Remain High”

In terms of indication, the breast cancer segment held about 24.5% of the total market share in 2021, and is expected to expand at a 9.7% CAGR over the forecast period. Various governments in underdeveloped nations are taking steps to stimulate research efforts aimed at producing cancer gene therapy and treatment plans to lower mortality and morbidity rates, which will drive growth in the cancer gene therapy market over the forecast period.

Which Service Provider Benefits the Most in the Cancer Gene Therapy Market?

“Adoption of Cancer Gene Therapy in Hospitals Will Increase”

By service provider, the hospitals segment will expand at a 9.3% CAGR over the assessment period. The presence of trained providers, as well as institutional facilities equipped with treatment options are some factors expected to drive sales in this segment in the forthcoming years.

Moreover, the availability of reimbursement plans for gene therapy will continue pushing sales over the forecast period.

Competitive Landscape

Leading cancer gene therapy manufacturers are focusing on technological advancements in order to increase revenue and expand their footprint in emerging markets through acquisitions, partnerships, and collaborations.

For instance:

  • In Sept 2021, Adaptimmune partnered with Genentech to develop allogeneic cell therapies indicated for multiple cancers.
  • In June 2021, Eisai and Bristol Myers Squibb agreed to collaborate on the development and commercialization of Eisai's ADC, MORAb-202, for advanced solid malignancies.
  • In June 2021, GSK and iTeos Therapeutics collaborated to develop EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for advanced solid malignancies.

Report Scope

Attribute

Details

Estimated Market Size (2022)

US$ 2 Bn

Projected Market Valuation (2032)

US$ 5.3 Bn

Value-based CAGR (2022-2032)

10.1%

Forecast Period 

2022-2032

Historical Data Available for 

2017-2021 

Market Analysis 

US$ Bn for Value  

Key Regions Covered 

North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa  

Key Countries Covered 

The U.S., Canada, Brazil, Mexico, Argentina, Germany, the U.K., France, Italy, Spain, Russia, Poland, Georgia China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, GCC Countries, Turkey, and South Africa 

Key Market Segments Covered 

Therapy, Indication, Service Provider, and Region

Key Companies Profiled 

  • Merck KGaA
  • Novartis AG
  • AstraZeneca Plc.
  • BIOCAD
  • Crinetics Pharmaceuticals, Inc.
  • EffRx Pharmaceuticals S.A.
  • Euroscreen S.A.
  • Vicore Pharma AB
  • Amgen
  • Bristol-Myers Squibb
  • Cell Genesys Inc.
  • Adaptimmune Therapeutics plc.
  • Achieve Life Science Inc.
  • BioCanCell Ltd.
  • Genelux Corporation
  • Advantagene Inc.,
  • GenVec Inc.
  • GlaxoSmithKline PLC
  • Amgen Inc.

Key Market Segments Covered in Cancer Gene Therapy Industry Research

By Therapy:

  • Gene Induced Immunotherapy
  • Oncolytic Virotherapy
  • Gene Transfer
  • Others

By Indication:

  • Breast Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Prostate Cancer

By Service Provider:

  • Hospitals
  • Clinical Research Laboratory
  • Oncology institutes

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

The global cancer gene therapy market is forecast to reach US$ 2 Bn in 2022 and is set to expand 2.6X over the forecast period.

The cancer gene therapy market is expected to reach US$ 5.3 Bn by end of 2032 at a CAGR of 10.1%

Key trends expected to drive sales in the market include increasing prevalence of cancer, rising awareness about healthcare practices among consumers, and an increase in the adoption of cancer gene therapy.

The key restraints affecting the cancer gene therapy market are the presence of alternatives to cancer gene therapy, the high cost involved in cancer gene therapy, and the shortage of skilled professionals.

North America held the highest market share of 52.8% by value in 2021 in the global cancer gene therapy market.

The U.S., the U.K., Germany, France, and Japan are the top five countries that are expected to drive demand in the cancer gene therapy market.

Merck KGaA, Novartis AG, AstraZeneca Plc. BIOCAD, Crinetics Pharmaceuticals, Inc., EffRx Pharmaceuticals S.A., Euroscreen S.A., Vicore Pharma AB, Amgen, Bristol-Myers Squibb, Cell Genesys Inc., Adaptimmune Therapeutics plc., Achieve Life Science Inc., BioCanCell Ltd., Genelux Corporation, Advantagene Inc., GenVec Inc., GlaxoSmithKline PLC, Amgen Inc. are the key manufacturers in this market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Technology Assessment

    4.2. Disease Epidemiology

    4.3. Regulatory Landscape

    4.4. Reimbursement Outlook

    4.5. Key Marketing & Promotional Strategies Adopted By Companies

    4.6. PESTLE Analysis

    4.7. Porter’s Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Rise in Healthcare Spending

        5.1.3. Global Expenditure on Healthcare Infrastructure

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Mergers and Acquisitions

        5.2.2. Disease Prevalence and Growth

        5.2.3. R&D for Cancer Gene Therapy

        5.2.4. Technological Advancements

        5.2.5. Regulatory Framework

        5.2.6. Reimbursement Policies

        5.2.7. Prevalence of Geriatric Age Group

        5.2.8. Global Burden of Cancer

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

    6.1. COVID-19 and Impact Analysis

        6.1.1. Revenue By Therapy

        6.1.2. Revenue By Indication

        6.1.3. Revenue By Service Provider

        6.1.4. Revenue By Country

    6.2. 2021 Market Scenario

7. Global Cancer Gene Therapy Market Demand (in Value or Size in US$ Bn) Analysis 2017–2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Bn) Analysis, 2017–2021

    7.2. Current and Future Market Value (US$ Bn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Cancer Gene Therapy Market Analysis 2017–2021 and Forecast 2022–2032, By Therapy

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Bn) Trend Analysis, By Therapy, 2017–2021

    8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Therapy, 2022–2032

        8.3.1. Gene Induced Immunotherapy

        8.3.2. Oncolytic Virotherapy

        8.3.3. Gene Transfer

        8.3.4. Others

    8.4. Market Attractiveness Analysis By Therapy

9. Global Cancer Gene Therapy Market Analysis 2017–2021 and Forecast 2022–2032, By Indication

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Bn) Trend Analysis, By Indication, 2017–2021

    9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Indication, 2022–2032

        9.3.1. Breast Cancer

        9.3.2. Ovarian Cancer

        9.3.3. Liver Cancer

        9.3.4. Pancreatic Cancer

        9.3.5. Lung Cancer

        9.3.6. Prostate Cancer

    9.4. Market Attractiveness Analysis By Indication

10. Global Cancer Gene Therapy Market Analysis 2017–2021 and Forecast 2022–2032, By Service Provider

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Bn) Trend Analysis, By Service Provider, 2017–2021

    10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Service Provider, 2022–2032

        10.3.1. Hospitals

        10.3.2. Clinical Research Laboratory

        10.3.3. Oncology institutes

    10.4. Market Attractiveness Analysis By Service Provider

11. Global Cancer Gene Therapy Market Analysis 2017–2021 and Forecast 2022–2032, by Region

    11.1. Introduction

    11.2. Historical Market Size (US$ Bn) Analysis, By Region, 2017–2021

    11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2022–2032

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. East Asia

        11.3.5. South Asia

        11.3.6. Oceania

        11.3.7. Middle East and Africa (MEA)

    11.4. Market Attractiveness Analysis By Region

12. North America Cancer Gene Therapy Market Analysis 2017–2021 and Forecast 2022–2032

    12.1. Introduction

    12.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021

    12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032

        12.3.1. By Country

            12.3.1.1. U.S.

            12.3.1.2. Canada

        12.3.2. By Therapy

        12.3.3. By Indication

        12.3.4. By Service Provider

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Therapy

        12.4.3. By Indication

        12.4.4. By Service Provider

    12.5. Market Trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

    12.8. Country Level Analysis & Forecast

        12.8.1. U.S. Cancer Gene Therapy Market Analysis

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast by Market Taxonomy

                12.8.1.2.1. By Therapy

                12.8.1.2.2. By Indication

                12.8.1.2.3. By Service Provider

        12.8.2. Canada Cancer Gene Therapy Market Analysis

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast by Market Taxonomy

                12.8.2.2.1. By Therapy

                12.8.2.2.2. By Indication

                12.8.2.2.3. By Service Provider

13. Latin America Cancer Gene Therapy Market Analysis 2017–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021

    13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032

        13.3.1.  By Country

            13.3.1.1. Mexico

            13.3.1.2. Brazil

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

        13.3.2. By Therapy

        13.3.3. By Indication

        13.3.4. By Service Provider

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Therapy

        13.4.3. By Indication

        13.4.4. By Service Provider

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. Mexico Cancer Gene Therapy Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Therapy

                13.8.1.2.2. By Indication

                13.8.1.2.3. By Service Provider

        13.8.2. Brazil Cancer Gene Therapy Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Therapy

                13.8.2.2.2. By Indication

                13.8.2.2.3. By Service Provider

        13.8.3. Argentina Cancer Gene Therapy Market Analysis

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast by Market Taxonomy

                13.8.3.2.1. By Therapy

                13.8.3.2.2. By Indication

                13.8.3.2.3. By Service Provider

14. Europe Cancer Gene Therapy Market Analysis 2017–2021 and Forecast 2022–2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021

    14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032

        14.3.1.  By Country

            14.3.1.1. Germany

            14.3.1.2. Italy

            14.3.1.3. France

            14.3.1.4. U.K.

            14.3.1.5. Spain

            14.3.1.6. BENELUX

            14.3.1.7. Nordic Countries

            14.3.1.8. Russia

            14.3.1.9. Rest of Europe

        14.3.2. By Therapy

        14.3.3. By Indication

        14.3.4. By Service Provider

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Therapy

        14.4.3. By Indication

        14.4.4. By Service Provider

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. Germany Cancer Gene Therapy Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Therapy

                14.8.1.2.2. By Indication

                14.8.1.2.3. By Service Provider

        14.8.2. Italy Cancer Gene Therapy Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Therapy

                14.8.2.2.2. By Indication

                14.8.2.2.3. By Service Provider

        14.8.3. France Cancer Gene Therapy Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Therapy

                14.8.3.2.2. By Indication

                14.8.3.2.3. By Service Provider

        14.8.4. U.K. Cancer Gene Therapy Market Analysis

            14.8.4.1. Introduction

            14.8.4.2. Market Analysis and Forecast by Market Taxonomy

                14.8.4.2.1. By Therapy

                14.8.4.2.2. By Indication

                14.8.4.2.3. By Service Provider

        14.8.5. Spain Cancer Gene Therapy Market Analysis

            14.8.5.1. Introduction

            14.8.5.2. Market Analysis and Forecast by Market Taxonomy

                14.8.5.2.1. By Therapy

                14.8.5.2.2. By Indication

                14.8.5.2.3. By Service Provider

        14.8.6. BENELUX Cancer Gene Therapy Market Analysis

            14.8.6.1. Introduction

            14.8.6.2. Market Analysis and Forecast by Market Taxonomy

                14.8.6.2.1. By Therapy

                14.8.6.2.2. By Indication

                14.8.6.2.3. By Service Provider

        14.8.7. Nordic Countries Contact Lenses Market Analysis

            14.8.7.1. Introduction

            14.8.7.2. Market Analysis and Forecast by Market Taxonomy

                14.8.7.2.1. By Therapy

                14.8.7.2.2. By Indication

                14.8.7.2.3. By Service Provider

        14.8.8.  Russia Cancer Gene Therapy Market Analysis

            14.8.8.1. Introduction

            14.8.8.2. Market Analysis and Forecast by Market Taxonomy

                14.8.8.2.1. By Therapy

                14.8.8.2.2. By Indication

                14.8.8.2.3. By Service Provider

15. East Asia Cancer Gene Therapy Market Analysis 2017–2021 and Forecast 2022–2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021

    15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Therapy

        15.3.3. By Indication

        15.3.4. By Service Provider

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Therapy

        15.4.3. By Indication

        15.4.4. By Service Provider

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. China Cancer Gene Therapy Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Therapy

                15.8.1.2.2. By Indication

                15.8.1.2.3. By Service Provider

        15.8.2. Japan Cancer Gene Therapy Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Therapy

                15.8.2.2.2. By Indication

                15.8.2.2.3. By Service Provider

        15.8.3. South Korea Cancer Gene Therapy Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Therapy

                15.8.3.2.2. By Indication

                15.8.3.2.3. By Service Provider

16. South Asia Cancer Gene Therapy Market Analysis 2017–2021 and Forecast 2022–2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021

    16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032

        16.3.1. By Country

            16.3.1.1. India

            16.3.1.2. Indonesia

            16.3.1.3. Malaysia

            16.3.1.4. Philippines

            16.3.1.5. Thailand

            16.3.1.6. Vietnam

            16.3.1.7. Rest of South Asia

        16.3.2. By Therapy

        16.3.3. By Indication

        16.3.4. By Service Provider

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Therapy

        16.4.3. By Indication

        16.4.4. By Service Provider

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. India Cancer Gene Therapy Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Therapy

                16.8.1.2.2. By Indication

                16.8.1.2.3. By Service Provider

        16.8.2. Indonesia Cancer Gene Therapy Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Therapy

                16.8.2.2.2. By Indication

                16.8.2.2.3. By Service Provider

        16.8.3. Malaysia Cancer Gene Therapy Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Therapy

                16.8.3.2.2. By Indication

                16.8.3.2.3. By Service Provider

        16.8.4. Philippines Cancer Gene Therapy Market Analysis

            16.8.4.1. Introduction

            16.8.4.2. Market Analysis and Forecast by Market Taxonomy

                16.8.4.2.1. By Therapy

                16.8.4.2.2. By Indication

                16.8.4.2.3. By Service Provider

        16.8.5. Thailand Cancer Gene Therapy Market Analysis

            16.8.5.1. Introduction

            16.8.5.2. Market Analysis and Forecast by Market Taxonomy

                16.8.5.2.1. By Therapy

                16.8.5.2.2. By Indication

                16.8.5.2.3. By Service Provider

        16.8.6. Vietnam Cancer Gene Therapy Market Analysis

            16.8.6.1. Introduction

            16.8.6.2. Market Analysis and Forecast by Market Taxonomy

                16.8.6.2.1. By Therapy

                16.8.6.2.2. By Indication

                16.8.6.2.3. By Service Provider

17. Oceania Cancer Gene Therapy Market 2012-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021

    17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032

        17.3.1.  By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Therapy

        17.3.3. By Indication

        17.3.4. By Service Provider

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Therapy

        17.4.3. By Indication

        17.4.4. By Service Provider

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. Australia Cancer Gene Therapy Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Therapy

                17.8.1.2.2. By Indication

                17.8.1.2.3. By Service Provider

        17.8.2. New Zealand Cancer Gene Therapy Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Therapy

                17.8.2.2.2. By Indication

                17.8.2.2.3. By Service Provider

18. Middle East and Africa (MEA) Cancer Gene Therapy Market Analysis 2017–2021 and Forecast 2022–2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021

    18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032

        18.3.1. By Country

            18.3.1.1. GCC Countries

            18.3.1.2. Israel

            18.3.1.3. Turkey

            18.3.1.4. South Africa

            18.3.1.5. North Africa

            18.3.1.6. Rest of Middle East and Africa

        18.3.2. By Therapy

        18.3.3. By Indication

        18.3.4. By Service Provider

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Therapy

        18.4.3. By Indication

        18.4.4. By Service Provider

    18.5. Market Trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country Level Analysis & Forecast

        18.8.1. GCC Countries Cancer Gene Therapy Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Therapy

                18.8.1.2.2. By Indication

                18.8.1.2.3. By Service Provider

        18.8.2. Israel Cancer Gene Therapy Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Therapy

                18.8.2.2.2. By Indication

                18.8.2.2.3. By Service Provider

        18.8.3. Turkey Cancer Gene Therapy Market Analysis

            18.8.3.1. Introduction

            18.8.3.2. Market Analysis and Forecast by Market Taxonomy

                18.8.3.2.1. By Therapy

                18.8.3.2.2. By Indication

                18.8.3.2.3. By Service Provider

        18.8.4. South Africa Cancer Gene Therapy Market Analysis

            18.8.4.1. Introduction

            18.8.4.2. Market Analysis and Forecast by Market Taxonomy

                18.8.4.2.1. By Therapy

                18.8.4.2.2. By Indication

                18.8.4.2.3. By Service Provider

        18.8.5. North Africa Cancer Gene Therapy Market Analysis

            18.8.5.1. Introduction

            18.8.5.2. Market Analysis and Forecast by Market Taxonomy

                18.8.5.2.1. By Therapy

                18.8.5.2.2. By Indication

                18.8.5.2.3. By Service Provider

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Share Analysis of Top Players

    19.3. Market Presence Analysis

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Competition Deep Dive

        20.3.1. Merck KGaA

            20.3.1.1. Overview

            20.3.1.2. Product Portfolio

            20.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.1.4. Sales Footprint

            20.3.1.5. Key Financials

            20.3.1.6. SWOT Analysis

            20.3.1.7. Strategy Overview

        20.3.2. Novartis AG

            20.3.2.1. Overview

            20.3.2.2. Product Portfolio

            20.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.2.4. Sales Footprint

            20.3.2.5. Key Financials

            20.3.2.6. SWOT Analysis

            20.3.2.7. Strategy Overview

        20.3.3. AstraZeneca Plc

            20.3.3.1. Overview

            20.3.3.2. Product Portfolio

            20.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.3.4. Sales Footprint

            20.3.3.5. Key Financials

            20.3.3.6. SWOT Analysis

            20.3.3.7. Strategy Overview

        20.3.4. BIOCAD

            20.3.4.1. Overview

            20.3.4.2. Product Portfolio

            20.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.4.4. Sales Footprint

            20.3.4.5. Key Financials

            20.3.4.6. SWOT Analysis

            20.3.4.7. Strategy Overview

        20.3.5. Crinetics Pharmaceuticals, Inc.

            20.3.5.1. Overview

            20.3.5.2. Product Portfolio

            20.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.5.4. Sales Footprint

            20.3.5.5. Key Financials

            20.3.5.6. SWOT Analysis

            20.3.5.7. Strategy Overview

        20.3.6. EffRx Pharmaceuticals S.A.

            20.3.6.1. Overview

            20.3.6.2. Product Portfolio

            20.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.6.4. Sales Footprint

            20.3.6.5. Key Financials

            20.3.6.6. SWOT Analysis

            20.3.6.7. Strategy Overview

        20.3.7. Euroscreen S.A.

            20.3.7.1. Overview

            20.3.7.2. Product Portfolio

            20.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.7.4. Sales Footprint

            20.3.7.5. Key Financials

            20.3.7.6. SWOT Analysis

            20.3.7.7. Strategy Overview

        20.3.8. Vicore Pharma AB

            20.3.8.1. Overview

            20.3.8.2. Product Portfolio

            20.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.8.4. Sales Footprint

            20.3.8.5. Key Financials

            20.3.8.6. SWOT Analysis

            20.3.8.7. Strategy Overview

        20.3.9. Amgen

            20.3.9.1. Overview

            20.3.9.2. Product Portfolio

            20.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.9.4. Sales Footprint

            20.3.9.5. Key Financials

            20.3.9.6. SWOT Analysis

            20.3.9.7. Strategy Overview

        20.3.10. Bristol-Myers Squibb

            20.3.10.1. Overview

            20.3.10.2. Product Portfolio

            20.3.10.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.10.4. Sales Footprint

            20.3.10.5. Key Financials

            20.3.10.6. SWOT Analysis

            20.3.10.7. Strategy Overview

        20.3.11. Cell Genesys Inc.

            20.3.11.1. Overview

            20.3.11.2. Product Portfolio

            20.3.11.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.11.4. Sales Footprint

            20.3.11.5. Key Financials

            20.3.11.6. SWOT Analysis

            20.3.11.7. Strategy Overview

        20.3.12. Adaptimmune Therapeutics plc

            20.3.12.1. Overview

            20.3.12.2. Product Portfolio

            20.3.12.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.12.4. Sales Footprint

            20.3.12.5. Key Financials

            20.3.12.6. SWOT Analysis

            20.3.12.7. Strategy Overview

        20.3.13. Achieve Life Science Inc.

            20.3.13.1. Overview

            20.3.13.2. Product Portfolio

            20.3.13.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.13.4. Sales Footprint

            20.3.13.5. Key Financials

            20.3.13.6. SWOT Analysis

            20.3.13.7. Strategy Overview

        20.3.14. BioCanCell Ltd.

            20.3.14.1. Overview

            20.3.14.2. Product Portfolio

            20.3.14.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.14.4. Sales Footprint

            20.3.14.5. Key Financials

            20.3.14.6. SWOT Analysis

            20.3.14.7. Strategy Overview

        20.3.15. Genelux Corporation

            20.3.15.1. Overview

            20.3.15.2. Product Portfolio

            20.3.15.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.15.4. Sales Footprint

            20.3.15.5. Key Financials

            20.3.15.6. SWOT Analysis

            20.3.15.7. Strategy Overview

        20.3.16. Advantagene Inc.,

            20.3.16.1. Overview

            20.3.16.2. Product Portfolio

            20.3.16.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.16.4. Sales Footprint

            20.3.16.5. Key Financials

            20.3.16.6. SWOT Analysis

            20.3.16.7. Strategy Overview

        20.3.17. GenVec Inc.

            20.3.17.1. Overview

            20.3.17.2. Product Portfolio

            20.3.17.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.17.4. Sales Footprint

            20.3.17.5. Key Financials

            20.3.17.6. SWOT Analysis

            20.3.17.7. Strategy Overview

        20.3.18. Glaxosmithkline PLC

            20.3.18.1. Overview

            20.3.18.2. Product Portfolio

            20.3.18.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.18.4. Sales Footprint

            20.3.18.5. Key Financials

            20.3.18.6. SWOT Analysis

            20.3.18.7. Strategy Overview

        20.3.19. Amgen Inc.

            20.3.19.1. Overview

            20.3.19.2. Product Portfolio

            20.3.19.3. Profitability by Market Segments (Product/Channel/Region)

            20.3.19.4. Sales Footprint

            20.3.19.5. Key Financials

            20.3.19.6. SWOT Analysis

            20.3.19.7. Strategy Overview

21. Assumptions and Acronyms Used

22. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Cancer Gene Therapy Market Value (US$ Bn) Forecast by Region, 2017 & 2032

Table 02: Global Cancer Gene Therapy Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032

Table 03: Global Cancer Gene Therapy Market Value (US$ Bn) Forecast by Indication, 2017 & 2032

Table 04: Global Cancer Gene Therapy Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032

Table 05: North America Cancer Gene Therapy Market Value (US$ Bn) Forecast by Country, 2017 & 2032

Table 06: North America Cancer Gene Therapy Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032

Table 07: North America Cancer Gene Therapy Market Value (US$ Bn) Forecast by Indication, 2017 & 2032

Table 08: North America Cancer Gene Therapy Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032

Table 09: Latin America Cancer Gene Therapy Market Value (US$ Bn) Forecast by Country, 2017 & 2032

Table 10: Latin America Cancer Gene Therapy Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032

Table 11: Latin America Cancer Gene Therapy Market Value (US$ Bn) Forecast by Indication, 2017 & 2032

Table 12: Latin America Cancer Gene Therapy Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032

Table 13: Europe Cancer Gene Therapy Market Value (US$ Bn) Forecast by Country, 2017 & 2032

Table 14: Europe Cancer Gene Therapy Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032

Table 15: Europe Cancer Gene Therapy Market Value (US$ Bn) Forecast by Indication, 2017 & 2032

Table 16: Europe Cancer Gene Therapy Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032

Table 17: East Asia Cancer Gene Therapy Market Value (US$ Bn) Forecast by Country, 2017 & 2032

Table 18: East Asia Cancer Gene Therapy Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032

Table 19: East Asia Cancer Gene Therapy Market Value (US$ Bn) Forecast by Indication, 2017 & 2032

Table 20: East Asia Cancer Gene Therapy Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032

Table 21: South Asia Cancer Gene Therapy Market Value (US$ Bn) Forecast by Country, 2017 & 2032

Table 22: South Asia Cancer Gene Therapy Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032

Table 23: South Asia Cancer Gene Therapy Market Value (US$ Bn) Forecast by Indication, 2017 & 2032

Table 24: South Asia Cancer Gene Therapy Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032

Table 25: Oceania Cancer Gene Therapy Market Value (US$ Bn) Forecast by Country, 2017 & 2032

Table 26: Oceania Cancer Gene Therapy Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032

Table 27: Oceania Cancer Gene Therapy Market Value (US$ Bn) Forecast by Indication, 2017 & 2032

Table 28: Oceania Cancer Gene Therapy Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032

Table 29: MEA Cancer Gene Therapy Market Value (US$ Bn) Forecast by Country, 2017 & 2032

Table 30: MEA Cancer Gene Therapy Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032

Table 31: MEA Cancer Gene Therapy Market Value (US$ Bn) Forecast by Indication, 2017 & 2032

Table 32: MEA Cancer Gene Therapy Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 01: Global Cancer Gene Therapy Market Value (US$ Bn) by Therapy, 2022 & 2032

Figure 02: Global Cancer Gene Therapy Market Value (US$ Bn) by Indication, 2022 & 2032

Figure 03: Global Cancer Gene Therapy Market Value (US$ Bn) by Service Provider, 2022 & 2032

Figure 04: Global Cancer Gene Therapy Market Value (US$ Bn) by Region, 2022 & 2032

Figure 05: Global Cancer Gene Therapy Market Value (US$ Bn) Analysis by Region, 2017 & 2032

Figure 06: Global Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Region, 2022 & 2032

Figure 07: Global Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 08: Global Cancer Gene Therapy Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032

Figure 09: Global Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032

Figure 10: Global Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 11: Global Cancer Gene Therapy Market Value (US$ Bn) Analysis by Indication, 2017 & 2032

Figure 12: Global Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032

Figure 13: Global Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 14: Global Cancer Gene Therapy Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032

Figure 15: Global Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032

Figure 16: Global Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032

Figure 17: Global Cancer Gene Therapy Market Attractiveness by Therapy, 2022-2032

Figure 18: Global Cancer Gene Therapy Market Attractiveness by Indication, 2022-2032

Figure 19: Global Cancer Gene Therapy Market Attractiveness by Service Provider, 2022-2032

Figure 20: Global Cancer Gene Therapy Market Attractiveness by Region, 2022-2032

Figure 21: North America Cancer Gene Therapy Market Value (US$ Bn) by Therapy, 2022 & 2032

Figure 22: North America Cancer Gene Therapy Market Value (US$ Bn) by Indication, 2022 & 2032

Figure 23: North America Cancer Gene Therapy Market Value (US$ Bn) by Service Provider, 2022 & 2032

Figure 24: North America Cancer Gene Therapy Market Value (US$ Bn) by Country, 2022 & 2032

Figure 25: North America Cancer Gene Therapy Market Value (US$ Bn) Analysis by Country, 2017 & 2032

Figure 26: North America Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 27: North America Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 28: North America Cancer Gene Therapy Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032

Figure 29: North America Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032

Figure 30: North America Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 31: North America Cancer Gene Therapy Market Value (US$ Bn) Analysis by Indication, 2017 & 2032

Figure 32: North America Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032

Figure 33: North America Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 34: North America Cancer Gene Therapy Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032

Figure 35: North America Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032

Figure 36: North America Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032

Figure 37: North America Cancer Gene Therapy Market Attractiveness by Therapy, 2022-2032

Figure 38: North America Cancer Gene Therapy Market Attractiveness by Indication, 2022-2032

Figure 39: North America Cancer Gene Therapy Market Attractiveness by Service Provider, 2022-2032

Figure 40: North America Cancer Gene Therapy Market Attractiveness by Country, 2022-2032

Figure 41: Latin America Cancer Gene Therapy Market Value (US$ Bn) by Therapy, 2022 & 2032

Figure 42: Latin America Cancer Gene Therapy Market Value (US$ Bn) by Indication, 2022 & 2032

Figure 43: Latin America Cancer Gene Therapy Market Value (US$ Bn) by Service Provider, 2022 & 2032

Figure 44: Latin America Cancer Gene Therapy Market Value (US$ Bn) by Country, 2022 & 2032

Figure 45: Latin America Cancer Gene Therapy Market Value (US$ Bn) Analysis by Country, 2017 & 2032

Figure 46: Latin America Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 47: Latin America Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 48: Latin America Cancer Gene Therapy Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032

Figure 49: Latin America Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032

Figure 50: Latin America Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 51: Latin America Cancer Gene Therapy Market Value (US$ Bn) Analysis by Indication, 2017 & 2032

Figure 52: Latin America Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032

Figure 53: Latin America Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 54: Latin America Cancer Gene Therapy Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032

Figure 55: Latin America Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032

Figure 56: Latin America Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032

Figure 57: Latin America Cancer Gene Therapy Market Attractiveness by Therapy, 2022-2032

Figure 58: Latin America Cancer Gene Therapy Market Attractiveness by Indication, 2022-2032

Figure 59: Latin America Cancer Gene Therapy Market Attractiveness by Service Provider, 2022-2032

Figure 60: Latin America Cancer Gene Therapy Market Attractiveness by Country, 2022-2032

Figure 61: Europe Cancer Gene Therapy Market Value (US$ Bn) by Therapy, 2022 & 2032

Figure 62: Europe Cancer Gene Therapy Market Value (US$ Bn) by Indication, 2022 & 2032

Figure 63: Europe Cancer Gene Therapy Market Value (US$ Bn) by Service Provider, 2022 & 2032

Figure 64: Europe Cancer Gene Therapy Market Value (US$ Bn) by Country, 2022 & 2032

Figure 65: Europe Cancer Gene Therapy Market Value (US$ Bn) Analysis by Country, 2017 & 2032

Figure 66: Europe Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 67: Europe Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 68: Europe Cancer Gene Therapy Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032

Figure 69: Europe Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032

Figure 70: Europe Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 71: Europe Cancer Gene Therapy Market Value (US$ Bn) Analysis by Indication, 2017 & 2032

Figure 72: Europe Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032

Figure 73: Europe Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 74: Europe Cancer Gene Therapy Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032

Figure 75: Europe Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032

Figure 76: Europe Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032

Figure 77: Europe Cancer Gene Therapy Market Attractiveness by Therapy, 2022-2032

Figure 78: Europe Cancer Gene Therapy Market Attractiveness by Indication, 2022-2032

Figure 79: Europe Cancer Gene Therapy Market Attractiveness by Service Provider, 2022-2032

Figure 80: Europe Cancer Gene Therapy Market Attractiveness by Country, 2022-2032

Figure 81: East Asia Cancer Gene Therapy Market Value (US$ Bn) by Therapy, 2022 & 2032

Figure 82: East Asia Cancer Gene Therapy Market Value (US$ Bn) by Indication, 2022 & 2032

Figure 83: East Asia Cancer Gene Therapy Market Value (US$ Bn) by Service Provider, 2022 & 2032

Figure 84: East Asia Cancer Gene Therapy Market Value (US$ Bn) by Country, 2022 & 2032

Figure 85: East Asia Cancer Gene Therapy Market Value (US$ Bn) Analysis by Country, 2017 & 2032

Figure 86: East Asia Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 87: East Asia Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 88: East Asia Cancer Gene Therapy Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032

Figure 89: East Asia Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032

Figure 90: East Asia Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 91: East Asia Cancer Gene Therapy Market Value (US$ Bn) Analysis by Indication, 2017 & 2032

Figure 92: East Asia Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032

Figure 93: East Asia Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 94: East Asia Cancer Gene Therapy Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032

Figure 95: East Asia Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032

Figure 96: East Asia Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032

Figure 97: East Asia Cancer Gene Therapy Market Attractiveness by Therapy, 2022-2032

Figure 98: East Asia Cancer Gene Therapy Market Attractiveness by Indication, 2022-2032

Figure 99: East Asia Cancer Gene Therapy Market Attractiveness by Service Provider, 2022-2032

Figure 100: East Asia Cancer Gene Therapy Market Attractiveness by Country, 2022-2032

Figure 101: South Asia Cancer Gene Therapy Market Value (US$ Bn) by Therapy, 2022 & 2032

Figure 102: South Asia Cancer Gene Therapy Market Value (US$ Bn) by Indication, 2022 & 2032

Figure 103: South Asia Cancer Gene Therapy Market Value (US$ Bn) by Service Provider, 2022 & 2032

Figure 104: South Asia Cancer Gene Therapy Market Value (US$ Bn) by Country, 2022 & 2032

Figure 105: South Asia Cancer Gene Therapy Market Value (US$ Bn) Analysis by Country, 2017 & 2032

Figure 106: South Asia Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 107: South Asia Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 108: South Asia Cancer Gene Therapy Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032

Figure 109: South Asia Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032

Figure 110: South Asia Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 111: South Asia Cancer Gene Therapy Market Value (US$ Bn) Analysis by Indication, 2017 & 2032

Figure 112: South Asia Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032

Figure 113: South Asia Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 114: South Asia Cancer Gene Therapy Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032

Figure 115: South Asia Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032

Figure 116: South Asia Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032

Figure 117: South Asia Cancer Gene Therapy Market Attractiveness by Therapy, 2022-2032

Figure 118: South Asia Cancer Gene Therapy Market Attractiveness by Indication, 2022-2032

Figure 119: South Asia Cancer Gene Therapy Market Attractiveness by Service Provider, 2022-2032

Figure 120: South Asia Cancer Gene Therapy Market Attractiveness by Country, 2022-2032

Figure 121: Oceania Cancer Gene Therapy Market Value (US$ Bn) by Therapy, 2022 & 2032

Figure 122: Oceania Cancer Gene Therapy Market Value (US$ Bn) by Indication, 2022 & 2032

Figure 123: Oceania Cancer Gene Therapy Market Value (US$ Bn) by Service Provider, 2022 & 2032

Figure 124: Oceania Cancer Gene Therapy Market Value (US$ Bn) by Country, 2022 & 2032

Figure 125: Oceania Cancer Gene Therapy Market Value (US$ Bn) Analysis by Country, 2017 & 2032

Figure 126: Oceania Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 127: Oceania Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 128: Oceania Cancer Gene Therapy Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032

Figure 129: Oceania Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032

Figure 130: Oceania Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 131: Oceania Cancer Gene Therapy Market Value (US$ Bn) Analysis by Indication, 2017 & 2032

Figure 132: Oceania Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032

Figure 133: Oceania Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 134: Oceania Cancer Gene Therapy Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032

Figure 135: Oceania Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032

Figure 136: Oceania Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032

Figure 137: Oceania Cancer Gene Therapy Market Attractiveness by Therapy, 2022-2032

Figure 138: Oceania Cancer Gene Therapy Market Attractiveness by Indication, 2022-2032

Figure 139: Oceania Cancer Gene Therapy Market Attractiveness by Service Provider, 2022-2032

Figure 140: Oceania Cancer Gene Therapy Market Attractiveness by Country, 2022-2032

Figure 141: MEA Cancer Gene Therapy Market Value (US$ Bn) by Therapy, 2022 & 2032

Figure 142: MEA Cancer Gene Therapy Market Value (US$ Bn) by Indication, 2022 & 2032

Figure 143: MEA Cancer Gene Therapy Market Value (US$ Bn) by Service Provider, 2022 & 2032

Figure 144: MEA Cancer Gene Therapy Market Value (US$ Bn) by Country, 2022 & 2032

Figure 145: MEA Cancer Gene Therapy Market Value (US$ Bn) Analysis by Country, 2017 & 2032

Figure 146: MEA Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 147: MEA Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 148: MEA Cancer Gene Therapy Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032

Figure 149: MEA Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032

Figure 150: MEA Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 151: MEA Cancer Gene Therapy Market Value (US$ Bn) Analysis by Indication, 2017 & 2032

Figure 152: MEA Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032

Figure 153: MEA Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 154: MEA Cancer Gene Therapy Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032

Figure 155: MEA Cancer Gene Therapy Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032

Figure 156: MEA Cancer Gene Therapy Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032

Figure 157: MEA Cancer Gene Therapy Market Attractiveness by Therapy, 2022-2032

Figure 158: MEA Cancer Gene Therapy Market Attractiveness by Indication, 2022-2032

Figure 159: MEA Cancer Gene Therapy Market Attractiveness by Service Provider, 2022-2032

Figure 160: MEA Cancer Gene Therapy Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Cancer Gene Therapy Market